<?xml version="1.0" encoding="UTF-8"?>
<ref id="B126">
 <label>126</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>De Simone</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>La Pietra</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Betari</surname>
    <given-names>N.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Discovery of the first-in-class GSK-3
   <italic>β</italic>/HDAC dual inhibitor as disease-modifying agent to combat Alzheimer’s disease
  </article-title>
  <source>
   <italic toggle="yes">ACS Medicinal Chemistry Letters</italic>
  </source>
  <year>2019</year>
  <volume>10</volume>
  <issue>4</issue>
  <fpage>469</fpage>
  <lpage>474</lpage>
  <pub-id pub-id-type="doi">10.1021/acsmedchemlett.8b00507</pub-id>
  <pub-id pub-id-type="other">2-s2.0-85061558627</pub-id>
  <?supplied-pmid 30996781?>
  <pub-id pub-id-type="pmid">30996781</pub-id>
 </element-citation>
</ref>
